|Articles|October 11, 2022
- Pharmaceutical Executive-10-01-2022
- Volume 42
- Issue 10
Pharmaceutical Executive, October 2022 Issue (PDF)
Advertisement
Articles in this issue
over 3 years ago
Healthy Planet, Healthy People: How Pharma Can Lead the Wayover 3 years ago
At the Heart of Pharma: ESG has Arrived as a Central Strategyover 3 years ago
Keeping it Simpleover 3 years ago
All About the Rates: The Fallout of Fed Hikes for Biotechover 3 years ago
Exploring Fixed and Variable Coverage Principlesover 3 years ago
Inclusion Check-In: Who are You Giving Your Energy To?over 3 years ago
Cracking the Code to Commercial Promise in Asiaover 3 years ago
Push for Full Embrace of Digital Care Draws Opposition in Europeover 3 years ago
Seeking Harmonized Testing, Regulation, and ManufacturingAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer
2
The Rise of Direct-to-Patient Models in Pharma: Opportunities and Risks in Bypassing Traditional Distribution Channels
3
Novartis Announces $105 Million Collaborative Agreement with Antares Therapeutics
4
The Economics of the 340B Drug Pricing Program: Strategic Imperatives for the Life Sciences Industry in 2026
5